CA2003692A1 - Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract and additional applications for surfactant replacement therapy and other conditions requiring rapid phospholipid _absorption to surfaces - Google Patents

Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract and additional applications for surfactant replacement therapy and other conditions requiring rapid phospholipid _absorption to surfaces

Info

Publication number
CA2003692A1
CA2003692A1 CA2003692A CA2003692A CA2003692A1 CA 2003692 A1 CA2003692 A1 CA 2003692A1 CA 2003692 A CA2003692 A CA 2003692A CA 2003692 A CA2003692 A CA 2003692A CA 2003692 A1 CA2003692 A1 CA 2003692A1
Authority
CA
Canada
Prior art keywords
mixtures
lipids
replacement therapy
compositions
surfactant replacement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2003692A
Other languages
French (fr)
Other versions
CA2003692C (en
Inventor
Lenard M. Lichtenberger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of CA2003692A1 publication Critical patent/CA2003692A1/en
Application granted granted Critical
Publication of CA2003692C publication Critical patent/CA2003692C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

Disclosed are methods employing compositions composed of unique mixtures of phospholipids and neutral lipids to treat the luminal lining of the gastrointestinal tract in the prevention or treatment of ulcerogenic processes such as peptic ulcer disease and inflammatory bowel disease. Compositions including mixtures of saturated or unsaturated phospholipids, together with saturated or unsaturated triglycerides and/or sterols, are shown to provide a surprising ulcer protective efficacy in experimental models. Further enhancement of activity is found upon the addition of a polyvalent cation or antioxidant to the various lipid mixtures. The present invention also discloses unique methods employing mixtures of phospholipids and nutral lipids for surfactant replacement therapy in the treatment of the various forms of respiratory distress syndrome. These compositions are shown to greatly enhance the surfactant replacement efficiency of surface-active lipids. In this regard, experimental models have shown that both the surface-tension lowering effect and rate of phospholipid absorption to an air/liquid interface are accelerated by the addition of triglycerides and/or sterols to mixtures of saturated or unsaturated phospholipids. Such compositions are therefore theorized to give new and enhanced therapeutic value to the use of surface-active lipids for surfactant replacement therapy in a subject without risk of immunogenic response. The subject methods also comprise a simple, rapid and inexpensive means for the deposition of polar lipids to a variety of air/liquid interfaces.
CA002003692A 1989-03-15 1989-11-23 Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract and additional applications for surfactant replacement therapy and other conditions requiring rapid phospholipid _absorption to surfaces Expired - Fee Related CA2003692C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
USC.I.P.323,671 1989-03-15
US07/323,671 US5032585A (en) 1987-02-17 1989-03-15 Methods and compositions employing unique mixtures of polar and neutral lipids for surfactant replacement therapy

Publications (2)

Publication Number Publication Date
CA2003692A1 true CA2003692A1 (en) 1990-09-15
CA2003692C CA2003692C (en) 1996-06-25

Family

ID=23260222

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002003692A Expired - Fee Related CA2003692C (en) 1989-03-15 1989-11-23 Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract and additional applications for surfactant replacement therapy and other conditions requiring rapid phospholipid _absorption to surfaces

Country Status (4)

Country Link
US (1) US5032585A (en)
EP (2) EP0401952A2 (en)
JP (1) JPH02279628A (en)
CA (1) CA2003692C (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256569A (en) * 1986-01-21 1993-10-26 Chisso Corporation Transesterification process for otereoselection of enantiomers of secondary alcohols using pseudomonas lipase with no added solvent
FR2658418B1 (en) * 1990-02-20 1994-09-02 Synthelabo PHARMACEUTICAL COMPOSITIONS BASED ON PHOSPHOLIPIDS.
ES2033193B1 (en) * 1990-10-30 1994-01-16 Ganadera Union Ind Agro FAT MIXTURE FOR CHILD AND ADULT NUTRITION.
GB9120005D0 (en) * 1991-09-19 1991-11-06 Wellcome Found Method of administering phospholipid dispersions
US5674855A (en) * 1992-08-12 1997-10-07 The Rogosin Institute Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions
US6764693B1 (en) * 1992-12-11 2004-07-20 Amaox, Ltd. Free radical quenching composition and a method to increase intracellular and/or extracellular antioxidants
US5478819A (en) * 1993-06-23 1995-12-26 Simo Tarpila Phospholipid composition and use thereof
US5763422A (en) * 1995-01-27 1998-06-09 Board Of Regents, The University Of Texas System Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein
US5955451A (en) * 1995-05-12 1999-09-21 The University Of Texas System Board Of Regents Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein
ID22744A (en) 1997-02-21 1999-12-09 Abbott Lab Cs METHODS AND COMPOSITIONS TO REDUCE THE INFLUENCE OF ENTERCOLYTIC NECROTISATION
US6080787A (en) * 1997-02-21 2000-06-27 Abbott Laboratories Methods for reducing the incidence of necrotizing enterocolitis
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20020017295A1 (en) * 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
ATE253369T1 (en) * 1998-08-06 2003-11-15 Wolfgang Stremmel PHOSPHATIDYLCHOLINE AS A MEDICINAL PRODUCT WITH A PROTECTIVE EFFECT FOR THE MUCOSA
US6677327B1 (en) 1999-11-24 2004-01-13 Archer-Daniels-Midland Company Phytosterol and phytostanol compositions
WO2001076577A2 (en) 2000-04-07 2001-10-18 The Board Of Regents Of The University Of Texas System Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced gi toxicity
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
ES2525087T5 (en) * 2000-05-10 2018-06-28 Novartis Ag Phospholipid-based powders for drug administration
NL1015288C2 (en) * 2000-05-24 2001-12-14 Peter Ferdinand Elbers Preparation for stabilizing the protective layer on the epithelium of the cornea or alveoli.
US20100173876A1 (en) * 2000-12-19 2010-07-08 The Board Of Regents Of The University Of Texas System Oil-based nsaid compositions and methods for making and using same
US20040077604A1 (en) 2001-12-19 2004-04-22 Lenard Lichtenberger Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity
ES2364636T3 (en) 2001-12-19 2011-09-08 Novartis Ag PULMONARY ADMINISTRATION OF AMINOGLUCOSIDS.
US20080051373A1 (en) * 2003-07-31 2008-02-28 The Board Of Regents Of The University Of Texas System Parenteral preparations of GI-safer phospholipid-associated anti-inflammatories and methods of preparation and use
WO2007005672A2 (en) * 2005-06-30 2007-01-11 The Scripps Research Institute Treatment and prevention of respiratory diseases and conditions
WO2007014754A1 (en) * 2005-08-02 2007-02-08 I.D.M. Immuno-Designed Molecules Process for the preparation of liposomal formulations
EP2046389A2 (en) 2006-07-19 2009-04-15 The Board of Regents of the University of Texas System Preparations of phospholipids and pharmaceuticals containing 5-amino salicylic acid for the treatment of inflammatory bowel disease
EP2061583B1 (en) * 2006-09-14 2019-04-10 Yissum Research Development Company, of The Hebrew University of Jerusalem Organic nanoparticles obtained from microemulsions by solvent evaporation
AR063704A1 (en) 2006-09-14 2009-02-11 Makhteshim Chem Works Ltd PESTICIDE NANOPARTICLES OBTAINED OBTAINED FROM MICROEMULSIONS AND NANOEMULSIONS
WO2012020279A1 (en) * 2010-08-13 2012-02-16 Compagnie Gervais Danone Product for the upper gastric sphere
KR102180667B1 (en) 2011-09-29 2020-11-20 피엘엑스 옵코 인코포레이티드 Ph dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
WO2019173884A1 (en) * 2018-03-15 2019-09-19 Bebeachibuli Romeo Biological normalizer, process for producing a biological normalizer and products produced with the biological normalizer
CN115666523A (en) 2020-03-26 2023-01-31 Plx 奥普科有限公司 Drug carriers capable of pH dependent reconstitution and methods of making and using the same

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE48402C (en) * J. G. STRODTMANN in Petersburg, County Menard, Illinois Sealing press with security lock
US3594476A (en) * 1969-05-12 1971-07-20 Massachusetts Inst Technology Submicron aqueous aerosols containing lecithin
US3715432A (en) * 1971-01-22 1973-02-06 Massachusetts Inst Technology Submicron aqueous aerosols containing lecithin
IT1085693B (en) * 1977-08-04 1985-05-28 Aesculapius Lab Chim Farma EXTRACTIVE PROCESS FOR THE PREPARATION OF PHOSPHOLIPIDES FROM ANIMALS, FOR THERAPEUTIC USE
US4287174A (en) * 1978-03-31 1981-09-01 The Proctor & Gamble Company Anti-ulcer composition
DE2856333C2 (en) * 1978-12-27 1983-09-22 A. Nattermann & Cie GmbH, 5000 Köln Oral medicines with anti-inflammatory effects
US4369182A (en) * 1978-09-27 1983-01-18 A. Nattermann & Cie Gmbh Inflammation-preventing pharmaceutical composition of oral administration
JPS609726B2 (en) * 1980-05-15 1985-03-12 株式会社 ミドリ十字 steroid preparations
US4312860A (en) * 1980-10-24 1982-01-26 Regents Of The University Of California Lung surfactant compositions
IL63734A (en) * 1981-09-04 1985-07-31 Yeda Res & Dev Lipid fraction,its preparation and pharmaceutical compositions containing same
JPS5848309A (en) * 1981-09-16 1983-03-22 オムロン株式会社 Contact mechanism
DE3374914D1 (en) * 1982-04-12 1988-01-28 Univ Texas Methods and compositions for treating gastro-intestinal ulcer diesease
JPS5995219A (en) * 1982-11-22 1984-06-01 Teijin Ltd Synthetic active substance for lung surface and remedy for respiratory distress syndrome containing said substance as active component
EP0110498B2 (en) * 1982-11-22 1991-09-18 Teijin Limited Artificial lung surfactant and remedy for respiratory distress syndrome containing it as active principle
US4542019A (en) * 1983-03-11 1985-09-17 John Lezdey Antacid compositions
CA1296640C (en) * 1985-07-26 1992-03-03 Meir Shinitzky Special lipid mixture for membrane fluidization
FR2586587B1 (en) * 1985-08-30 1987-10-23 Adir NEW ARTIFICIAL SURFACTANTS, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US4918063A (en) * 1987-02-17 1990-04-17 Board Of Regents, The University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract

Also Published As

Publication number Publication date
EP0406998A3 (en) 1993-06-23
EP0406998A2 (en) 1991-01-09
JPH02279628A (en) 1990-11-15
US5032585A (en) 1991-07-16
CA2003692C (en) 1996-06-25
EP0401952A2 (en) 1990-12-12

Similar Documents

Publication Publication Date Title
CA2003692A1 (en) Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract and additional applications for surfactant replacement therapy and other conditions requiring rapid phospholipid _absorption to surfaces
EP0287198A3 (en) Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastronointestinal tract
FI840615A (en) FOER FRAMSTAELLNING AV LAEKEMEDELSADSORBAT LAEMPLIGT MAGNESIUMTRISILIKAT.
NO160579C (en) ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE OMEGA (1,4,5-TRIFENYLIMIDAZOL-2-YLOXY) ALKANIC ACIDS AND THEIR DERIVATIVES.
IN153855B (en)
GB2070429B (en) Use of perfluorocarbon as burn treatment
NO151822C (en) ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE ESTERS OF ACYL CARNITINES
NO160521C (en) ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 13ALFA ALKYLGONANES.
AU558711B2 (en) Enzyme preparation for treatment of liver and kidney disease
CA2196906A1 (en) Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions
NO157175C (en) ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE AROYLIMIDAZOLONS.
NO810675L (en) PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE TETRAZOLD DERIVATIVES.
FR2555050B1 (en) PHARMACEUTICAL COMPOSITIONS AND PROCESS FOR THE PREPARATION OF PHOSPHATIDYLSERINE COMPOSITIONS FOR USE IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM WITHOUT EFFECTS ON BLOOD COAGULATION
NO167510C (en) ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE PHENYLKINOLINCARBOXYL ACIDS
IL58299A0 (en) Fluorine containing 1,4-derivatives,their production and their medicinal use
AU3518984A (en) Administration of gangliosides by inhalation
NO814055L (en) PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE THIENOPYRIDINO DERIVATIVES
NO149737C (en) ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 1-AZAXANTHON-3-CARBOXYLIC ACIDS
DK619484A (en) PHARMACEUTICAL PREPARATION AGAINST RHEUMATIC DISORDERS
NO811346L (en) PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE ADENOSIN DERIVATIVES.
SE8702784D0 (en) COMPOSITION
IT8048347A0 (en) 6-SUBSTITUTED PYRANONE COMPOUNDS FOR THE TREATMENT OF HYPERSENSITIVE CONDITIONS SUCH AS ASTHMA AND PROCEDURE FOR THEIR PREPARATION
NO160779C (en) ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 2-METOXYPHENYL ESTERS.
NO165292C (en) ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE AZABICYCLO (3.3.1) NONANES.
US4657934A (en) Method for treating Herpes simplex virus infection and topical preparation used therein

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed